Blast Phase and High-Risk Features

While the majority of patients with PDGFRB-rearranged neoplasms respond exceptionally well to imatinib, a small number of cases are more aggressive or can change over time. Understanding these high-risk features and the signs of disease progression can help you and your medical team act quickly if the “chronic phase” begins to shift ^[1][2].

Defining the Blast Phase

The most significant change is the progression to the blast phase (sometimes called a blast crisis). This occurs when the bone marrow stops producing functional blood cells and instead produces an abundance of “blasts”—immature, non-functional cells that would normally be seen in acute leukemia ^[2].

This phase is generally defined by having 20% or more blasts in your marrow or blood. It can take several forms:

• Myeloid Blast Phase: Acts like Acute Myeloid Leukemia (AML) ^[1].
• Lymphoid Blast Phase: Acts like Acute Lymphoblastic Leukemia (ALL) or lymphoma ^[1][3].
• Extramedullary Disease: Sometimes, the cancer cells form masses in other parts of the body, such as the lymph nodes, skin, or other organs ^[2][4].

High-Risk Genetic Features

Doctors look for specific genetic clues to identify cases that might be harder to treat. These are often referred to as high-risk features:

• Complex Karyotype: This means your cells have multiple different chromosome abnormalities beyond just the PDGFRB rearrangement. In small studies, patients with a complex karyotype had a higher risk of the disease returning ^[1].
• Co-occurring Mutations: Using advanced tests like Next-Generation Sequencing (NGS), doctors may find mutations in other genes, such as ASXL1, RUNX1, SETBP1, or TET2 ^[5][6]. While these are not always a “death sentence,” they often suggest the disease is more complex and may be less likely to stay in remission with imatinib alone ^[5].
• Persistent Fibrosis: Significant scarring in the bone marrow that does not improve with treatment can sometimes be a sign of a more stubborn disease ^[5].

When Imatinib Stops Working: Resistance

In very rare cases, the cancer cells can develop a “point mutation”—a tiny, specific change in the PDGFRB protein itself. This mutation can physically block imatinib from “plugging in” to turn the switch off ^[7]. If your blood counts start to rise or the fusion gene reappears on sensitive tests despite taking your medication, your doctor will likely order a kinase domain mutation analysis to see if resistance has developed ^[7].

Treatment for High-Risk Disease

If the disease reaches the blast phase or becomes resistant to imatinib, the treatment strategy must change significantly. Imatinib alone is generally not enough to control the disease at this stage ^[1].

• Intensive Chemotherapy: Doctors usually combine a TKI (like imatinib or a second-generation TKI) with the kind of intensive chemotherapy used for acute leukemia ^[8][9].
• Stem Cell Transplant: For many in the blast phase, an allogeneic hematopoietic stem cell transplant (using a donor’s cells) is considered the best chance for a long-term cure ^[1][9]. However, transplant decisions depend on many factors, including your age, fitness, lineage, and response to initial therapy, and are not automatically required for everyone. Because the outcomes for blast phase can be challenging, identifying a donor early is often a priority ^[1].

Monitoring for Progression

The best way to manage these risks is through the consistent monitoring we have discussed. Catching a rising blast count or a new mutation early—before it causes significant symptoms—gives your care team the best opportunity to adjust your treatment and keep the disease under control ^[1][10].